Abstracts tagged "neurology"

Abstract Number: 1380 • ACR Convergence 2025
Phenotyping Neuropathic Pain in Sjögren’s Disease: A Cluster-Based Approach
Beatrice Dei¹, Stefano Donati¹, Gaetano La Rocca², Giovanni Fulvio¹, Federico Fattorini¹, Antonello Sulis¹, Michele Moretti¹, Elena Elefante¹, Francesco Ferro³, Giulia Ricci⁴, Marta Mosca⁵ and Chiara Baldini⁵, ¹Rheumatology Unit, University of Pisa, Pisa, Toscana, Italy, ²University of Pisa, Rheumatology Unit, Pisa, Pisa, Italy, ³Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Pisa, Italy, ⁴Neurology Unit, University of Pisa, Pisa, Toscana, Italy, ⁵University of Pisa, Pisa, Pisa, Italy
Background/Purpose: Neuropathic pain (NeP) is increasingly recognized as a relevant symptom domain in primary Sjögren’s disease (SjD), contributing to the disease burden beyond glandular involvement.…
Abstract Number: 1378 • ACR Convergence 2025
Prevalence of Central Nervous System Manifestations in Sjögren’s Disease
Arun Varadhachary¹, Ghaith Noaiseh², Katherine Hammitt³, Julie Frantsve-Hawley³, Paula Barreras Cortes⁴, Shamik Bhattacharyya⁵, E. Sherwood Brown⁶, Drew Carey⁷, Robert Fox⁸, Brent Goodman⁹, Thomas Grader-Beck¹⁰, Janet Lewis¹¹, Stephen Maitz¹², Steven Mandel¹³, Jenifer McCombe¹⁴, Astrid Rasmussen¹⁵, George Sarka¹⁶, Daniel Wallace¹⁷, Frederick Vivino¹⁸, Rochelle Zak¹⁹, Nancy Carteron²⁰, R Hal Scofield¹⁵ and Steven Carsons²¹, ¹Washington University in St. Louis, St. Louis, MO, ²University of Kansas Medical Center, Kansas City, KS, ³Sjogren's Foundation, Reston, VA, ⁴Cedars Sinai, Los Angeles, CA, ⁵Brigham and Women's Hospital, Malden, MA, ⁶UT Southwestern Medical Center, Dallas, TX, ⁷Johns Hopkins University School of Medicine, Baltimore, MD, ⁸Rheumatology Clinic, San Diego, CA, ⁹HonorHealth, Scottsdale, AZ, ¹⁰Johns Hopkins, Reisterstown, MD, ¹¹University of Virginia, Charlottesville, VA, ¹²U.S. Department of Veterans Affairs, Coatesville, PA, ¹³Donald and Barbara Zucker School of Medicine and Hofstra/Northwell, Hempstead, NY, ¹⁴University of Alberta, Edmonton, AB, Canada, ¹⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁶Cedars-Sinai Medical Center, Laguna Hills, CA, ¹⁷Cedars Sinai Medical Center, Studio City, CA, ¹⁸University of Pennsylvania, Bryn Mawr, PA, ¹⁹UCSF Health, San Francisco, CA, ²⁰University of California, Berkeley & San Francisco, Angwin, CA, ²¹NYU Long Island School of Medicine, Mineola, NY
Background/Purpose: Sjögren’s disease is a systemic autoimmune disorder with diverse clinical manifestations affecting multiple organ systems. While dry mouth, dry eyes, fatigue and pain are…
Abstract Number: 1095 • ACR Convergence 2025
Tolerance of non-TNF α treatments in patient with an inflammatory rheumatic (IRD) and autoimmune demyelinating diseases: French retrospective cases series
dellal azeddine¹, Jean-Guillaume Letarouilly², Jacques Morel³, René-Marc Flipo⁴, Valerie Devauchelle⁵, richette pascal⁶, Philippe Dieude⁷, Hubert Marotte⁸, FELTEN Renaud⁹, LATOURTE Augustin¹⁰, CHEVET Baptiste¹¹, HILLIQUIN Pascal¹², SORDET Christelle⁹, DERNIS mmanuelle¹³, WENDLING Daniel¹⁴, Arsène Mekinian¹⁵, Nathalie BALLANDRAUD¹⁶, Christophe Richez¹⁷, TOURNADRE Anne¹⁸, salmon Jean -Hugues¹⁹, SAILLOT Carine²⁰, kedra joanna²¹, nahon stephane²², LE GOFF Benoit²³, Bruno Fautrel²⁴, Francis BERENBAUM²⁵, David SAADOUN²⁶, PHAM Thao¹⁶ and SELLAM JEREMIE²⁷, ¹GHI LE RAINCY MONTFERMEIL, Montfermeil, France, ²Université de Lille, CHU Lille, Service de rhumatologie, Lille, France, LILLE, Nord-Pas-de-Calais, France, ³CHU and University of Montpellier, Montpellier, France, ⁴Université de Lille, CHU Lille, Service de rhumatologie, Lille, France, Lille, France, ⁵UBO, Brest, France, ⁶Rheumatology Department, Lariboisiere Hospital, Paris, Ile-de-France, France, ⁷Service de Rhumatologie, Hôpital Bichat APHP, Paris, Paris, Ile-de-France, France, ⁸INSERM ¹⁰⁵⁹/University of Saint-Etienne, Saint-Etienne, France, ⁹Service de Rhumatologie, Centre de référence des maladies auto-immunes rares (RESO), Hôpitaux Universitaires de Strasbourg, Strasbourg, Strasbourg, Alsace, France, ¹⁰Rheumatology Department, Lariboisiere Hospital, Paris, France, ¹¹CHU BREST, brest, Bretagne, France, ¹²CH SUD FRANCILIEN, PARIS, France, ¹³chu caen, CAEN, Haute-Normandie, France, ¹⁴CHU de Besançon, Besançon, Franche-Comte, France, ¹⁵Department of Internal Medicine, Inflammation-Immunopathology-Biotherapy Department (DMU i³), Saint-Antoine University Hospital, ⁷⁵⁰¹² Paris, France, Paris, France, ¹⁶CHU MARSEILLE, marseille, Provence-Alpes-Cote d'Azur, France, ¹⁷Bordeaux University Hospital, Bordeaux, France, ¹⁸CHU CLERMONT, CLERMONT, Lorraine, France, ¹⁹CHU REIMS, REIMS, Champagne-Ardenne, France, ²⁰CHU ORLEANS, ORLEANS, Pays de la Loire, France, ²¹Pitié-Salpêtrière Hospital, Rheumatology Department, APHP, Sorbonne University,, Paris, France, ²²GHI LE RAINCY MONTFERMEIL, Montfermeil, Ile-de-France, France, ²³CHU Nantes, Nantes, France, ²⁴Sorbonne Université - APHP, Department of Rheumatology, Hôpital Pitié-Salpêtrière, Inserm UMRS ¹¹³⁶-⁵, PARIS, France, Paris, France, ²⁵Sorbonne University/Inserm/AP-HP/⁴Moving Biotech, Paris, France, ²⁶CHU LA PITIE SALPETRIERE, PARIS, Ile-de-France, France, ²⁷Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, CRSA, F-⁷⁵⁰¹² Paris, France, /Rheumatology Department, AP-HP Saint-Antoine Hospital, ¹⁸⁴, rue du Faubourg Saint-Antoine, ⁷⁵⁰¹², Paris, France., Paris, France
Background/Purpose: The use of TNFα antagonist is not recommended if the patient have a suspicion or demyelinating diseases (DD) confirmed [1]. There are a few…
Abstract Number: 2481 • ACR Convergence 2024
General, Nervous System, Eye, and Skin Involvement in the Phase 3 Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis
Rula A. Hajj-Ali¹, Duvuru Geetha², Raashid Luqmani³, Christian Pagnoux⁴, Darcy Trimpe⁵, David Jayne⁶ and Peter Merkel⁷, and ADVOCATE Study Group, ¹Cleveland Clinic, Cleveland, OH, ²Johns Hopkins University, Baltimore, MD, ³University of Oxford, Abingdon, United Kingdom, ⁴Mount Sinai Hospital, Toronto, ON, Canada, ⁵Amgen Inc., Thousand Oaks, CA, ⁶University of Cambridge, Cambridge, United Kingdom, ⁷University of Pennsylvania, Philadelphia, PA
Background/Purpose: The most common types of ANCA-associated vasculitis, granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), can affect a range of organs, including the kidneys,…
Abstract Number: 0311 • ACR Convergence 2024
Investigation of Sarcoidosis-associated Neuropathy: Challenges with Diagnosis of Small Fiber Neuropathy
Kristen Caldwell¹, Sindhuja Koppu¹, Kelly Gwathmey¹, Aamer Syed¹, Jordana Kron¹, Thomas Iden¹ and Huzaefah Syed², ¹Virginia Commonwealth University, Richmond, VA, ²Virginia Commonwealth University Medical Center, Richmond, VA
Background/Purpose: Small fiber neuropathy (SFN) is an underrecognized complication of sarcoidosis which can significantly impair individuals’ physical functioning and quality of life. Diagnosis includes both…
Abstract Number: PP09 • ACR Convergence 2024
Finding the Balance: Regaining My Strength While Living with Sjögren’s & POTS
Robert Fearon, Sjögren's Foundation, Reston, VA
Background/Purpose: Like many suffering from autoimmune diseases, my diagnosis was not straightforward and took nearly 13 years to get answers. I first started experiencing an…
Abstract Number: 0312 • ACR Convergence 2024
The Use of Electromyography as a Screening Tool in Sarcoidosis-associated Neuropathy
Kristen Caldwell¹, Sindhuja Koppu¹, Huzaefah Syed², Aamer Syed¹, Jordana Kron¹, Thomas Iden¹ and Kelly Gwathmey¹, ¹Virginia Commonwealth University, Richmond, VA, ²Virginia Commonwealth University Medical Center, Richmond, VA
Background/Purpose: Small fiber neuropathy (SFN) is the most common peripheral nervous system manifestation of sarcoidosis. Diagnosis of SFN includes clinical evaluation, occasionally skin biopsy to…
Abstract Number: 0363 • ACR Convergence 2024
Comparative Risk of Demyelinating Diseases Among Patients on TNF-Alpha Inhibitors: A Cohort Study Using the TriNetX Database
Rafal Ali¹, Yurilu Gonzalez Moret², Roua Hussein³ and Fabian Rodriguez⁴, ¹Jefferson Einstein Philadelphia, Lansdale, PA, ²Jefferson Einstein Philadelphia, Philadelphia, PA, ³Al-Mustansiriyah University/ college of medicine, New York, NY, ⁴Jefferson Einstein Hospital, Philadelphia, PA
Background/Purpose: TNF-alpha inhibitors are widely used in the field of rheumatology and have been linked to various possible adverse events, including demyelinating diseases. This association…
Abstract Number: 0844 • ACR Convergence 2024
Effectiveness and Safety of the Recombinant Zoster Vaccine in Patients ≥18 Years of Age with Systemic Lupus Erythematosus or Multiple Sclerosis
Sheryl Kluberg¹, Sophie E. Mayer², O’Mareen Spence³, Driss Oraichi⁴, Harry Seifert⁴, Omar Ali³, Huifeng Yun⁴, Andrew L. Simon⁵, Jenice S. Ko⁶, Caroline Hugh⁷, Meg Her⁷, Kathleen Shattuck⁷, Richard Platt⁸, Aziza Jamal-Allial⁹, Djeneba Audrey DJIBO¹⁰, Kimberly Daniels¹¹, Qianli Ma¹², Cheryl N McMahill-Walraven¹⁰, Rachel P. Ogilvie¹³, Kristin Palmsten¹⁴, Mano Selvan¹⁵, Najat Ziyadeh¹⁶, Alexis Ogdie¹⁷ and Michael George¹⁸, ¹Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, ²Harvard Pilgrim Health Care Institute, Durham, ³GSK, Rockville, ⁴GSK, Rockville, MD, ⁵Harvard Pilgrim Healthcare Institute, Boston, MA, ⁶Harvard Pilgrim Health Care Ins􀆟tute, Boston, MA, ⁷Harvard Pilgrim Health Care Institute, Boston, MA, ⁸Harvard Pilgrim Health Care Institute / Harvard Medical School, Boston, MA, ⁹Carelon Research, Elevance Health, Newton, ¹⁰CVS Health, Blue Bell, ¹¹Carelon Research, Elevance Health, Wilmington, ¹²Humana Healthcare Research, Inc., Louisville, ¹³Optum, Boston, MA, ¹⁴HealthPartners Institute, Minneapolis, ¹⁵Humana Healthcare Research, Sugar Land, Texas, ¹⁶Optum, Baltimore, MD, ¹⁷Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ¹⁸University of Pennsylvania, Philadelphia, PA
Background/Purpose: The recombinant zoster vaccine (RZV) is US Food and Drug Administration-approved for the prevention of herpes zoster (HZ, shingles) in adults ≥50 years, and…
Abstract Number: 0926 • ACR Convergence 2024
Macrophages and Nociceptor Neurons Form a Sentinel Unit Around Fenestrated Capillaries to Defend the Synovium from Systemic Challenges
Tetsuo Hasegawa and Menna Clatworthy, University of Cambridge, Cambridge, United Kingdom
Background/Purpose: A wide variety of systemic pathologies, including infectious and autoimmune diseases, are accompanied by joint pain or inflammation, often mediated by circulating immune complexes…
Abstract Number: 1092 • ACR Convergence 2024
Chronic Kidney Disease Is Associated with Increased Glucose Uptake-associated Metabolic Activity of Visceral Adipose and Subcutaneous Adipose Tissue in Gout Patients
Shunya Kaneshita¹, Sho Fukui², Soheil Niku³, KWANGHOON LEE⁴, Ernest Belezzuoli³, Robert Terkeltaub⁵ and Monica Guma⁶, ¹UCSD, Miyazu city, Kyoto, Japan, ²Brigham and Women's Hospital, Brookline, MA, ³UCSD, La Jolla, ⁴UCSD, San Diego, CA, ⁵Retired, San Diego, CA, ⁶UCSD, La Jolla, CA
Background/Purpose: Gout, a condition characterized by elevated uric acid levels, is linked to multiple complications, including coronary artery disease, hypertension, and type 2 diabetes mellitus.…
Abstract Number: 1093 • ACR Convergence 2024
Risk of Dementia in Patients with Gout: Potential Impact of Survival Bias
Joshua Baker¹, Lindsay Helget², chung-Chou Chang³, Bryant England², Brian Coburn¹, Harlan Sayles², Punyasha Roul⁴ and Ted Mikuls², ¹University of Pennsylvania, Philadelphia, PA, ²University of Nebraska Medical Center, Omaha, NE, ³University of Pittsburgh, Pittsburgh, PA, ⁴UNMC, Omaha, NE
Background/Purpose: Prior studies reported a lower risk of dementia among patients with gout suggesting that hyperuricemia might play a neuroprotective role. However, risk estimates for…
Abstract Number: 1164 • ACR Convergence 2024
IVIG Treatment Duration in Immune-mediated Necrotizing Myopathy and a Possible Association of Vacuolar Changes with Black/African American Female Patients
Asim Mohamed¹, Liron Caplan² and Melissa Griffith³, ¹PGY5, Aurora, CO, ²Rocky Mountain Regional VAMC, Aurora, CO, ³University of Colorado, Aurora, CO
Background/Purpose: Immune Mediated Necrotizing Myopathy (IMNM) is a debilitating but understudied entity. Correlations of demographic and clinical features with pathological findings remain underexplored. In addition,…
Abstract Number: 1227 • ACR Convergence 2024
Longitudinal Patterns of Fibromyalgia Phenotypes in Patients with Systemic Lupus Erythematosus
Brooke Cohen¹, Philip Carlucci², Kelly Corbitt³, Mala Masson⁴, Amit Saxena⁵, H Michael Belmont⁵, Chung-E Tseng⁶, Rachel Wu⁷, Hamleini Martinez⁷, George Kenefati⁷, Lisa Doan⁷, Jing Wang⁸, Kamil Barbour⁹, Heather Gold⁷, Jill Buyon¹⁰ and Peter Izmirly¹¹, ¹NYU Langone, NYC, NY, ²New York University School of Medicine, New York, NY, ³University of Miami Miller School of Medicine, El Portal, FL, ⁴NYU Langone Medical Center- Division of Rheumatology, New York, NY, ⁵NYU School of Medicine, New York, NY, ⁶NYU Langone Health, Flushing, NY, ⁷NYU Langone Health, NYC, ⁸NYU Langone Health, NYC, NY, ⁹CDC, Alpharetta, GA, ¹⁰NYU Grossman School of Medicine, New York, NY, ¹¹New York University Grossman School of Medicine, New York, NY
Background/Purpose: Fibromyalgia (FM) is a common comorbidity in patients with systemic lupus erythematosus (SLE) and a major contributor to poor health related quality of life.…
Abstract Number: 1276 • ACR Convergence 2024
Therapeutic Drug Monitoring (TDM) of Rituximab to Predict Early B-Cell Repopulation in Children
Rana Alsulami¹, Bindiya Chugani², Joley Johnstone², Ann Yeh², Floris Loeff³, Linda Hiraki², Andrea Knight⁴, Deborah Levy² and Ruud Verstegen², ¹University of Toronto, Toronto, ON, Canada, ²The Hospital for Sick Children, Toronto, ON, Canada, ³Sanquin Diagnostic Services, Amsterdam, Netherlands, ⁴Division of Rheumatology, The Hospital for Sick Children; Neurosciences and Mental Health, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada
Background/Purpose: Rituximab is increasingly used in pediatric inflammatory diseases, with dosing extrapolated from adult data due to a lack of pediatric-specific pharmacokinetic (PK) information. Children…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].